Xu CR - Search Results

1

Bioinformatics analysis identifies miR-221 as a core regulator in hepatocellular carcinoma and its silencing suppresses tumor properties.

He XX, Guo AY, Xu CR, Chang Y, Xiang GY, Gong J, Dan ZL, Tian DA, Liao JZ, Lin JS. He XX, et al. Among authors: xu cr. Oncol Rep. 2014 Sep;32(3):1200-10. doi: 10.3892/or.2014.3306. Epub 2014 Jul 3. Oncol Rep. 2014. PMID: 24993451

2

Downregulation of MiR-93 expression reduces cell proliferation and clonogenicity of HepG2 cells.

Xu D, He XX, Chang Y, Sun SZ, Xu CR, Lin JS. Xu D, et al. Among authors: xu cr. Hepatogastroenterology. 2012 Nov-Dec;59(120):2367-73. doi: 10.5754/hge12458. Hepatogastroenterology. 2012. PMID: 22773266

3

Inhibition of miR-96 expression reduces cell proliferation and clonogenicity of HepG2 hepatoma cells.

Xu D, He X, Chang Y, Xu C, Jiang X, Sun S, Lin J. Xu D, et al. Oncol Rep. 2013 Feb;29(2):653-61. doi: 10.3892/or.2012.2138. Epub 2012 Nov 14. Oncol Rep. 2013. PMID: 23151657

4

Co-delivery of doxorubicin and Bmi1 siRNA by folate receptor targeted liposomes exhibits enhanced anti-tumor effects in vitro and in vivo.

Yang T, Li B, Qi S, Liu Y, Gai Y, Ye P, Yang G, Zhang W, Zhang P, He X, Li W, Zhang Z, Xiang G, Xu C. Yang T, et al. Theranostics. 2014 Aug 24;4(11):1096-111. doi: 10.7150/thno.9423. eCollection 2014. Theranostics. 2014. PMID: 25285163 Free PMC article.

5

A novel hydrolysis-resistant lipophilic folate derivative enables stable delivery of targeted liposomes in vivo.

Huang Y, Yang T, Zhang W, Lu Y, Ye P, Yang G, Li B, Qi S, Liu Y, He X, Lee RJ, Xu C, Xiang G. Huang Y, et al. Int J Nanomedicine. 2014 Sep 29;9:4581-95. doi: 10.2147/IJN.S69115. eCollection 2014. Int J Nanomedicine. 2014. PMID: 25302024 Free PMC article.

6

Validation of Bmi1 as a therapeutic target of hepatocellular carcinoma in mice.

Qi S, Li B, Yang T, Liu Y, Cao S, He X, Zhang P, Li L, Xu C. Qi S, et al. Int J Mol Sci. 2014 Nov 3;15(11):20004-21. doi: 10.3390/ijms151120004. Int J Mol Sci. 2014. PMID: 25372945 Free PMC article.

7

The regulation of microRNA expression by DNA methylation in hepatocellular carcinoma.

He XX, Kuang SZ, Liao JZ, Xu CR, Chang Y, Wu YL, Gong J, Tian DA, Guo AY, Lin JS. He XX, et al. Among authors: xu cr. Mol Biosyst. 2015 Feb;11(2):532-9. doi: 10.1039/c4mb00563e. Epub 2014 Nov 26. Mol Biosyst. 2015. PMID: 25424171

8

Gold nanoparticles delivered miR-375 for treatment of hepatocellular carcinoma.

Xue HY, Liu Y, Liao JZ, Lin JS, Li B, Yuan WG, Lee RJ, Li L, Xu CR, He XX. Xue HY, et al. Among authors: xu cr. Oncotarget. 2016 Dec 27;7(52):86675-86686. doi: 10.18632/oncotarget.13431. Oncotarget. 2016. PMID: 27880727 Free PMC article.

9

Antitumor activity of a folate receptor-targeted immunoglobulin G-doxorubicin conjugate.

Yang T, Xu L, Li B, Li W, Ma X, Fan L, Lee RJ, Xu C, Xiang G. Yang T, et al. Int J Nanomedicine. 2017 Mar 30;12:2505-2515. doi: 10.2147/IJN.S125591. eCollection 2017. Int J Nanomedicine. 2017. PMID: 28408821 Free PMC article.

10

Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma.

Xue H, Yu Z, Liu Y, Yuan W, Yang T, You J, He X, Lee RJ, Li L, Xu C. Xue H, et al. Int J Nanomedicine. 2017 Jul 24;12:5271-5287. doi: 10.2147/IJN.S135306. eCollection 2017. Int J Nanomedicine. 2017. PMID: 28769563 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

204 results

Search Page

Filters